# BNP Paribas Exane

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/bnp-paribas-exane
Canonical HTML page: https://getbiobrief.com/entity/bnp-paribas-exane

## Recent coverage (1 stories)

### ARE Q2 Revenue $662.78M: What Biotech Tenants Should Expect from FY’26 Guidance
2026-08-12 00:14:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

As the dominant landlord to pharma and startup labs, Alexandria’s FY 2026 EPS guidance of $6.35-$6.45—and its Q2 revenue beat of $662.78M—carry major implications for R&D real estate costs. While lease rates keep rising, a -36% net margin hints at stress in the sector that could eventually impact tenant concessions and space availability.
Full story: https://getbiobrief.com/story/alexandria-biotech-tenant-implications-fy26

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.